财务数据显示，截至2024年12月31日，川控股实现营业总收入7.65亿元，同比增长18.97%；归母净利润 4332.15万元，同比增长150.88%；毛利率13.19%，资产负债率46.14%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 5月22日，截至港股收盘，恒生指数下跌1.19%，报23544.31点。川控股（01420.HK）收报0.104港元/ 股，上涨9.47%，成交量2.8万股，成交额2880港元，振幅8.42%。 最近一个月来，川控股累计跌幅26.92%，今年来累计跌幅4.04%，跑输恒生指数18.78%的涨幅。 行业估值方面，建筑行业市盈率（TTM）平均值为10.63倍，行业中值1.51倍。川控股市盈率2.57倍，行 业排名第7位；其他浦江国际（02060.HK）为1.01倍、饮食天王(环球)（08619.HK）为1.39倍、中国管 业（00380.HK）为1.5倍、进升集团控股（01581.HK）为1.51倍、靛蓝星（08373.HK）为1.58倍。 资料显示，川控股有限公司为新加坡建筑业提供土方工程服务已有逾20年经验,根据欧睿报告,于2014年, 本公司为新加坡建筑业五大 ...

5月21日，菱电电控今日收盘55.58元，下跌3.02%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到87.15倍，总市值28.80亿元。 武汉菱电汽车电控系统股份有限公司的主营业务是发动机管理系统、纯电动汽车动力电子控制系统、混 合动力汽车动力电子控制系统、车联网产品以及相关的技术开发及标定服务。公司的主要产品是汽油 EMS、混合动力EMS、两用燃料（汽油、CNG）汽车EMS、摩托车EMS、电机控制器、发电机控制 器、整车控制器、T-BOX、电机电控二合一、HECU、四合一电机控制器、PCU、GECU发电三合一、 动力车身域控制器。 最新一期业绩显示，2025年一季报，公司实现营业收入3.12亿元，同比21.55%；净利润1747.60万元， 同比4521.16%，销售毛利率18.59%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)193菱电电控87.15180.591.7528.80亿行业平均 43.4046.303.7787.09亿行业中值36.5938.683.0749.24亿1长春一东-2985.83-1279.096.3829.69亿2圣龙股 份-2302.60157. ...

2连板乐山电力：公司市盈率远高于同行业上市公司均值 智通财经5月21日电，乐山电力(600644.SH)公告称，公司股票在2025年5月19日至21日连续三个交易日 内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。自4月11日以来，公司股价累计涨 幅达118.23%，显著高于同期上证指数涨幅4.61%。目前公司市盈率（TTM）为333.73，远高于同行业上 市公司均值27.14。 ...

文 | 银行螺丝钉 （转载请注明出处） 1 . A股 常见的四类指数 A股常见的指数，主要分为四类。 第一类是宽基指数。 通常是按照上市公司的市值规模来选股的，会包含各个行业的股票，覆盖范围很"宽"。 一、【直播回放】 有朋友问，价值策略有啥特征？ 300价值、优选300、中证价值，这些价值指数有啥区别？当前投资价值如何呢？ 在昨晚的直播课里，螺丝钉详细介绍了这些问题。 长按识别下面二维码，添加 @课程小助手 微信，回复「 0520 」即可观看直播回放。 （提示：回复后可以耐心等待几秒哦～） 二、【部分直播课内容如下】 第二类是策略指数。 通常是在宽基指数的基础上，用了某一种投资策略，覆盖的行业也会比较广泛。 策略指数丰富了我们投资的选项，满足了很多投资者个性化的需求。 第三类是行业指数。 也就是仅覆盖了某个行业的股票，例如消费、医药、金融等。最常见的行业指数，是11个一级行业。 每个一级行业，其实都是社会不可或缺的一部分，长期也是跟着社会发展的。 第四类是主题指数。 所包含的股票，跟某个主题密切相关，例如科技、新能源、人工智能等。 主题指数，通常会横跨多个行业，但达不到宽基指数的行业覆盖程度。 2 . 常见 ...

Group 1 - The core viewpoint of the article highlights the performance and valuation of Aidi Te (爱迪特), indicating a recent stock price increase and a low rolling PE ratio compared to the industry average [1] - As of May 20, Aidi Te's closing price was 56.11 yuan, with a rolling PE ratio of 26.95, marking a new low in 31 days, and a total market capitalization of 4.271 billion yuan [1] - The company ranks 59th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [2] Group 2 - Aidi Te experienced a net outflow of 351,100 yuan in principal funds on May 20, with a total outflow of 1.749 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of dental restoration materials and the design and sales of dental digital equipment [1] - In the latest quarterly report for Q1 2025, Aidi Te achieved an operating income of 205 million yuan, a year-on-year increase of 18.07%, and a net profit of 31.271 million yuan, reflecting a year-on-year growth of 34.21% with a gross profit margin of 51.00% [1]

隔夜，现货黄金大幅涨逾1%，日内最高涨至3249.02美元，最低至3205.04美元，最终收报于3229.30美 元。今日欧市盘中，黄金窄幅震荡，目前在3234美元附近徘徊。 事关降息！ 隔夜，美股一度低开，标普500指数、纳指盘初一度跌超1%，后抹平跌幅转涨，最终美股三大指数集体 收涨。截至收盘，道琼斯工业指数、纳斯达克指数、标普500指数分别涨0.32%、0.02%、0.09%。 消息面上，一则利空消息引发猛烈抛售。 约联储总裁威廉姆斯表示（给市场打气），我们没有看到外国资金流入美国国债市场的方式发生重大变 化。投资者已经并将继续认为，美国是一个绝佳的投资目的地，包括美国国债和固定收益资产，我认为 这种说法仍然存在。 明尼亚波利斯联储主席卡什卡利表示（呼唤市场的信心），从长期来看，保持投资者信心是决定政府借 款利率是否保持可控的关键问题之一。 美联储显示出在主权评级危机面前，愿意承担起稳定市场预期的角色，由此平息恐慌。 不过，美国亚特兰大联储主席博斯蒂克在采访中表达了他对未来物价上涨的预期，认为通胀正在朝着令 人不安的方向发展。因此，他倾向于今年只降息一次。据此前发布的点阵图，美联储官员们预计今年将 有两 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhenghai Biological, which closed at 20.38 yuan, with a PE ratio of 30.35, marking a new low in 23 days, and a total market capitalization of 3.668 billion yuan [1] - Zhenghai Biological ranks 67th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1] - As of March 31, 2025, Zhenghai Biological had 16,966 shareholders, a decrease of 193 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business of Zhenghai Biological involves the research, production, and sales of bio-regenerative materials, including oral repair membranes, absorbable dura mater patches, bone repair materials, and surgical sponges [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023, as announced by the Shandong Provincial Department of Industry and Information Technology [1] - In the latest quarterly report for Q1 2025, Zhenghai Biological reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, and a net profit of 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongjing Life, which closed at 14.12 yuan with a PE ratio of 58.28, marking a new low in 30 days, and a total market capitalization of 2.302 billion yuan [1] - The company operates in the in vitro diagnostic products sector, focusing on research, production, and sales of its own brand products, including diagnostic reagents and instruments [1] - The latest financial results for Q1 2025 show a revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, while net profit increased by 110.51% to 471,700 yuan, with a gross margin of 63.66% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device sector is 49.51, with a median of 36.17, positioning Tongjing Life at the 92nd rank within the industry [2] - The company has actively engaged in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1]

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The company operates in three main business segments: biomaterials, pharmaceuticals, and cells, and is committed to improving brand influence and market share [2] Financial Performance - For Q1 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] - The current stock price is 13.45 yuan, with a rolling PE ratio of 127.86, marking a new low in 30 days, and a total market capitalization of 3.566 billion yuan [1] Market Position - In the medical device industry, the average PE ratio is 49.51, and the median is 36.17, placing Guanhao Biological at the 110th position in terms of PE ratio [1][3] - As of May 9, 2025, the number of shareholders is 28,900, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

5月20日，理邦仪器今日收盘11.92元，上涨1.19%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到36.62倍，总市值69.10亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 截至2025年一季报，共有2家机构持仓理邦仪器，其中其他2家，合计持股数4877.75万股，持股市值5.91 亿元。 深圳市理邦精密仪器股份有限公司的主营业务是从事医疗电子设备产品和体外诊断产品的研发、生产、 销售、服务。公司的主要产品是急危重症监护方案、床旁监护方案、智能生命体征查房方案、静态心 电、运动心电、动态心电/血压、心电网络解决方案、推车式全数字彩色超声诊断系统、便携式全数字 彩色超声诊断系统、全数字超声诊断系统、手持式超声诊断系统、围产监护方案、妇科诊疗方案、盆底 康复方案、血气分析仪、采血器、软件管理产品、磁敏荧光免疫分析仪、血细胞分析仪、分子诊断产 品、智慧健康业务。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，理邦仪器排 名第76位。 来 ...